Biopath Hikes On International Patents

(MENAFN- Baystreet) Akamai Jumps on New Product

  • Eagle Soars on Test Data Release
  • TG Posts Gains on Results of MS Drug Test
  • Goldman Sachs Suggests Gold could move to $2,700 per ounce this year
  • Five of the Top Artificial Intelligence Stocks to Buy and Hold Today Previous Articles Subscribe to Get Small Cap News & Alerts Glenn Wilkins - Monday, April 15, 2024

    BioPath Hikes on International Patents

    Bio-Path Holdings, Inc., (NASDAQ:BPTH) shares leap Monday, as the Houston-based biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the receipt of newly issued patents in Mexico, Australia and Japan, and updated investors on the extent of its global intellectual property portfolio.

    Bio-Path has expanded its intellectual property portfolio by filing patent applications that are applicable to its technology and business strategy. Bio-Path's patent portfolio currently includes five issued patents in the U.S. and 54 issued patents in foreign jurisdictions, providing protection in 21 countries.

    According to this morning's news release,“These composition patents, including composition and methods of use patents covering the DNAbilize technology, should allow the Company to apply its core technology to new protein targets and receive an additional 20-years of patent exclusivity. On this basis, Bio-Path has one additional patent application allowed in the U.S. and five additional patent applications allowed in foreign jurisdictions, for a total of six additional patent grants expected this year.”

    “We continue our efforts to build protection around our platform as it safeguards our technology, is a deterrent to would-be competitors and creates value around our core competencies,” said CEO Peter Nielsen.“These efforts are designed to protect our investments and advance our clinical programs to bring new medicines to patients suffering with cancer.”

    BPTH shares came out of the chute higher by 37 cents, or 12.1%, Monday to $3.42.

    • About Us
    • Contact Us
    • Advertise
    • License Our Content
    • Jobs
    • Disclaimer
    • Privacy Policy

    Copyright 1998 - 2024 Baystreet Media Corp. All rights reserved. Nasdaq Stocks: Information delayed 15 minutes. Non-Nasdaq Stocks: Information delayed 20 minutes. Bid and Ask quotation information for NYSE and AMEX securities is only available on a real time basis. Market Data is provided by QuoteMedia. Earnings by Zacks. Analyst Ratings by Zacks



    Legal Disclaimer:
    MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.